

Eleftherios Pelechas · Evripidis Kaltsonoudis ·
Paraskevi V. Voulgari · Alexandros A. Drosos

Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases

Second Edition

 Springer

Eleftherios Pelechas
Department of Internal Medicine
Ioannina Medical School
Rheumatology Clinic
University of Ioannina
Ioannina, Greece

Evrpidis Kaltsonoudis
Department of Internal Medicine
Ioannina Medical School
Rheumatology Clinic
University of Ioannina
Ioannina, Greece

Paraskevi V. Voulgari
Department of Internal Medicine
Ioannina Medical School
Rheumatology Clinic
University of Ioannina
Ioannina, Greece

Alexandros A. Drosos
Department of Internal Medicine
Ioannina Medical School
Rheumatology Clinic
University of Ioannina
Ioannina, Greece

ISBN 978-3-031-47378-4

This book has been awarded by the National Academy of

Athens. 1st edition: © Springer Nature Switzerland AG 2019

2nd edition: © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Paper in this product is recyclable.

“To our patients who not only trusted their health, but also allowed us to take photos of their clinical manifestations in order to teach students and other health professionals”

“To all the medical, nursing and supporting staff who worked in the rheumatology clinic all these years and gave battles against pain, giving hope, courage and strength to our patients”

Preface

Rheumatology is a medical speciality that provides diagnosis and management of patients suffering from autoimmune rheumatic diseases (ARD) and chronic inflammatory arthritis. The majority of the above disorders are systemic, involving one or more organs and systems. The first signs of a rheumatic disease may implicate cutaneous, mucosal, ophthalmic and joint manifestations. Thus, it is mandatory for physicians to perform a minute and detailed physical examination of these systems, in order to reach a correct diagnosis. The necessity of the present second edition of the *Illustrated Handbook of Rheumatic and Musculoskeletal Diseases* relies on the new knowledge regarding the disease pathophysiology, diagnosis and treatment, which have been emerged over the last five years. Indeed, with the introduction of the new classification criteria and diagnostic tests for many rheumatic diseases, early recognition of them is now possible. Furthermore, the International and European authorities and organizations have approved new targeting agents, targeting components of the immune system and many biological therapies are now available and are used in these patients. On the other hand, targeting different proteins and cells of the immune system have led to several new paradoxical inflammatory manifestations. All the above are incorporated in the new second edition of the present book. As in the first edition, the philosophy of this book relies on less text and more figures, in order to make the reader confident and familiar to recognize easily different aspects of a rheumatic disease.

For this reason, a new chapter regarding ARD pathophysiology and immunological tests, along with two chapters dealing with disease monitoring and musculoskeletal ultrasonography, has been added. Moreover, another chapter covering the whole spectrum of spondyloarthropathies was also included. More than 100 new figures, clinical, imaging and histopathological pictures have been included.

Every chapter is divided into three parts. The first part with a general description of the disease including introduction, epidemiology, signs and symptoms, diagnostic modalities and management. The second part includes figures, clinical findings, imaging and histological pictures with a short, or detailed explanation according to the case presented. The last part includes old and new references and suggestions for further reading.

We hope that this second edition of the *Illustrated Handbook of Rheumatic and Musculoskeletal Diseases* will become a valuable guide and educator for training physicians, general practitioners, medical students, orthopaedics, and specialists in the field as well as other medical specialities.

Ioannina, Greece

Alexandros A. Drosos

Acknowledgements

We wish to especially thank **Haralambos M. Moutsopoulos**, Professor/Chair Immunology-Medicine Athens Academy, for his expert guidance and unconditional support who have helped us bring this second edition to life. We would also like to thank **Athanasios G. Tzioufas**, Professor/Director of the Department of Pathophysiology, School of Medicine, University of Athens, for his kind assistance. In addition, **Angelina Patsi** who agreed to act as model for the clinical examination, **Katerina Giannoutsou** and **Chrysa Arvaniti** for the secretarial support and **Stavroula Pelecha** for the language editing.

Finally, we feel honoured for the following expert contributors

Dimitra Archimandriti

Biochemist
Immunology Laboratory
University of Ioannina, Greece

Maria Argyropoulou

Professor of Radiology
University Hospital of Ioannina, Greece

Ioannis Bassukas

Professor of Dermatology
University Hospital of Ioannina, Greece

Georgios Gaitanis

Assistant Professor of Dermatology
University Hospital of Ioannina, Greece

Hara Gakiopoulou

Professor
Department of Pathology
National and Kapodistrian University, Athens, Greece

Anna Gousia

Professor
Department of Pathology
University of Ioannina, Greece

Christos Kalogeropoulos

Professor in Ophthalmology
University Hospital of Ioannina, Greece

Panagiota Karagianni

Biopathologist
University Hospital of Ioannina, Greece

Athanasios Kavvadias

Gastroenterologist
University Hospital of Ioannina, Greece

Paraskevi Konsta

Consultant Radiologist
University Hospital of Ioannina, Greece

Theodora Markatseli

Senior Registrar in Rheumatology
University Hospital of Ioannina, Greece

Alexandra Papoudou-Bai

Assistant Professor
Department of Pathology
University Hospital of Ioannina, Greece

Charalampos Sfontouris

Consultant Rheumatologist
Evangelismos Hospital, Greece

Polyxeni Spyrou

Laboratory Technician
Immunology Laboratory
University of Ioannina

Nikolaos Tsigaridas

Cardiologist
Hatzikosta General Hospital, Greece

Fotios Tsogkas

Ophthalmologist
Moorfields Eye Hospital, London, UK

Anastasia Zikou

Associate Professor

Department of Radiology

University Hospital of Ioannina, Greece

Katerina Zioga

Consultant Pathologist

University Hospital of Ioannina, Greece

Contents

1	Examination of the Musculoskeletal System.....	1
	Introduction	2
	Clinical Examination	2
	Imaging Modalities.....	3
	References and Further Reading	22
2	Autoimmune Rheumatic Diseases: Pathophysiology and Laboratory Tests.....	23
	Introduction	24
	Non-specific Laboratory Markers	24
	Specific Laboratory Markers in Rheumatology.....	24
	Autoantibodies	25
	Elements of Pathophysiology	28
	References and Further Reading	49
3	Disease Metrics and Activity Scores	51
	Introduction	52
	DAS-28—Disease Activity Score 28 (Rheumatoid Arthritis)	52
	SDAI/CDAI—Simplified/Clinical Disease Activity Index (Rheumatoid Arthritis)	53
	ASDAS—Ankylosing Spondylitis Disease Activity Score	53
	BASDAI—Bath Ankylosing Spondylitis Disease Activity Index.....	54
	DAPSA and DAPSA 28 (Psoriatic Arthritis)	55
	ESSPRI—EULAR Sjögren’s Syndrome Disease Activity Index.....	56
	Five-Factor Score (for Systemic Necrotizing Vasculitides)	56
	Summary of the Scores Used in Rheumatology	57
	References	65
		xiii
xiv		Contents
4	Musculoskeletal Ultrasound in Rheumatology.....	69

	History	70
	Introduction	70
	Application of Ultrasound in Rheumatology	71
	Elementary Lesions by OMERACT Study Group	72
	OMERACT Semiquantitative Scale for Joint Assessment.....	73
	EULAR Standardization of the Ultrasound Examination	73
	References and Further Reading.....	110
5	Rheumatoid Arthritis.....	113
	Introduction	114
	Epidemiology	114
	Risk Factors.....	114
	Signs and Symptoms	114
	Diagnosis and Differential Diagnosis	115
	Diagnostic Modalities.....	116
	Pathophysiology	117
	Management	117
	References and Further Reading.....	146
6	Sjögren's Syndrome	149
	Introduction	150
	Epidemiology	150
	Aetiopathogenesis	150
	Classification Criteria	151
	Signs and Symptoms	151
	Diagnosis and Differential Diagnosis	152
	Management	153
	References and Further Reading.....	162
7	Spondyloarthropathies	165
	Introduction	166
	Evolution of the Classification Criteria in SpA.....	167
	SpA Pathophysiology	168
	Imaging	169
	Management	170
	References and Further Reading.....	170
8	Ankylosing Spondylitis.....	173
	Introduction	174
	Epidemiology	174
	Aetiopathogenesis	174
	Classification Criteria	175
	Signs and Symptoms	175
	Differential Diagnosis.....	176
	Diagnostic Modalities.....	176
	Radiographic Changes.....	177
Contents		xv
	8.9 Management	178
	References and Further Reading	193

9	Psoriatic Arthritis	195
	9.1 Introduction	196
	9.2 Epidemiology	196
	9.3 Signs and Symptoms	196
	9.4 Diagnostic Modalities	197
	9.5 Management	198
	References and Further Reading	224
10	Systemic Lupus Erythematosus	227
	10.1 Introduction	228
	10.2 Aetiology and Pathogenesis	228
	10.3 Epidemiology	228
	10.4 Classification Criteria	229
	10.5 Signs and Symptoms	229
	10.6 Differential Diagnosis	231
	10.7 Diagnostic Modalities	231
	10.8 Management	232
	References and Further Reading	255
11	Scleroderma	257
	11.1 Introduction	258
	11.2 Epidemiology	258
	11.3 Aetiopathogenesis	258
	11.4 Classification Criteria	259
	11.5 Signs and Symptoms	259
	11.6 Differential Diagnosis	260
	11.7 Diagnostic Modalities	261
	11.8 Management	261
	References and Further Reading	291
12	Inflammatory Myopathies	293
	12.1 Introduction	294
	12.2 Aetiopathogenesis	294
	12.3 Epidemiology	295
	12.4 Signs and Symptoms	295
	12.5 Diagnostic Modalities	296
	12.6 Management	297
	References and Further Reading	317
13	Vasculitides	319
	13.1 Introduction	320
	13.2 Aetiology and Pathogenesis	320
	13.3 Epidemiology	320
	13.4 Nomenclature and Classification	321

- 13.5 Signs and Symptoms 321
- 13.6 Diagnostic Modalities 322
- 13.7 Management 323
- References and Further Reading 339
- 14 Osteoarthritis 341**
 - 14.1 Introduction 342
 - 14.2 Epidemiology 342
 - 14.3 Aetiopathogenesis 342
 - 14.4 Signs and Symptoms 343
 - 14.5 Diagnostic Modalities 343
 - 14.6 Management 344
 - References and Further Reading 363
- 15 Crystal Arthropathies 365**
 - 15.1 Introduction 366
 - 15.2 Epidemiology 366
 - 15.3 Aetiopathogenesis 367
 - 15.4 Classification Criteria 367
 - 15.5 Signs and Symptoms 368
 - 15.6 Diagnostic Modalities 368
 - 15.7 Management 370
 - References and Further Reading 379
- 16 Osteoporosis 381**
 - 16.1 Introduction 382
 - 16.2 Osteoporosis Types 382
 - 16.3 Aetiology 383
 - 16.4 Diagnostic Modalities 383
 - 16.5 Management 383
 - References and Further Reading 394
- 17 Sarcoidosis 395**
 - 17.1 Introduction 396
 - 17.2 Epidemiology 396
 - 17.3 Aetiopathogenesis 396
 - 17.4 Clinical Manifestations 396
 - 17.5 Diagnostic Approach 398
 - 17.6 Management 398
 - References 404
- 18 Miscellaneous Conditions 405**
 - 18.1 Relapsing Polychondritis 406
 - 18.1.1 Introduction 406
 - 18.1.2 Epidemiology 406
 - 18.1.3 Clinical Manifestations 406
 - 18.1.4 RP Associated Disorders 407

- Pathogenesis 407
- Diagnosis 407
- Management 409
- Diffuse Idiopathic Skeletal Hyperostosis (DISH)..... 409
- Introduction 409
- Epidemiology 410
- Clinical Manifestations..... 410
- Differential Diagnosis 411
- Treatment 411
- References and Further Reading 455
- 19 Adverse Drug Reactions in Rheumatology 457**
 - Introduction 458
 - Corticosteroids 458
 - Cyclosporine..... 459
 - Methotrexate..... 459
 - Hydroxychloroquine..... 459
 - Biologics..... 459
 - Others 460
 - References and Further Reading 484

Abbreviations

β2-GPI	Beta2-glycoprotein I
AAV	ANCA-associated vasculitis
ACE	Angiotensin-converting enzyme
ACL	Anterior cruciate ligament
aCL	Anticardiolipin
ACPA	Anti-citrullinated peptide antibodies
ACR	American College of Rheumatology
ADR	Adverse drug reactions
AIHA	Autoimmune haemolytic anaemia
ALT	Alanine aminotransferase
ANA	Antinuclear antibodies
ANCA	Antineutrophil cytoplasmic antibodies
anti-CCP	Anti-cyclic citrullinated peptide
AOSD	Adult-onset Still's disease
aPL	Antiphospholipid
aPTT	Activated partial thromboplastin time
ARD	Autoimmune rheumatic disease
AS	Ankylosing spondylitis
ASAS	Assessment of spondyloarthritis international society
ASDAS	Ankylosing spondylitis disease activity score
ASS	Antisynthetase syndrome
AxSpA	Axial spondyloarthropathy
AZA	Azathioprine
BASDAI	Bath ankylosing spondylitis disease activity index
BASFI	Bath ankylosing spondylitis functional index
BASMI	Bath ankylosing spondylitis metrology index
BCP	Basic calcium phosphate
bDMARDs	Biologic disease-modifying antirheumatic drugs
BICLA	BILAG-based composite lupus assessment
BILAG	British Isles lupus assessment group index
BME	Bone marrow edema

BMI	Body mass index
cANCA	Cytoplasmic antineutrophil cytoplasmic antibodies
CASPAR	Classification criteria for psoriatic arthritis
CBP	Chronic back pain
CCLE	Chronic cutaneous lupus erythematosus
CD	Colour Doppler
CDAI	Clinical disease activity index
CHB	Congenital heart block
CL	Cutaneous lupus
CLE	Cutaneous lupus erythematosus
CMC	Carpometacarpal joint
COPD	Chronic obstructive pulmonary disease
COX-2	Cyclooxygenase-2
CP	Cyclophosphamide
CPDAI	Composite psoriatic disease activity index
CPFE	Combined pulmonary fibrosis and emphysema
CPPD	Calcium pyrophosphate dihydrate disease
CR	Conventional radiography
CRP	C-reactive protein
Cryo	Cryoglobulin
CS	Corticosteroids
CSA	Cyclosporine
csDMARDs	Conventional synthetic disease-modifying antirheumatic drugs
CT	Computed tomography
CTD	Connective tissue disease
CTLA-4	Cytotoxic T-lymphocyte antigen 4
CTS	Carpal tunnel syndrome
CXR	Chest X-ray
DAPSA	Disease activity index for psoriatic arthritis
DAS-28	Disease activity score-28
DECT	Dual-energy computed tomography
DEXA	Dual-energy X-ray absorptiometry scan
DIP	Distal interphalangeal joint
DISH	Diffuse idiopathic skeletal hyperostosis
DLE	Discoid lupus erythematosus
DM	Dermatomyositis
DMARDs	Disease-modifying antirheumatic drugs
dRVVT	Dilute Russell's viper venom time
ds-DNA	Double-stranded DNA
DSM	Dermatomyositis sine myositis
EF	Eosinophilic fasciitis
EGPA	Eosinophilic granulomatosis with polyangiitis
ELISA	Enzyme-linked immunosorbent assay
ELP	Electrophoresis

EMG	Electromyography
EN	Erythema nodosum
ENA	Extractable nuclear antigens
ERAP-1	Endoplasmic reticulum aminopeptidase-1
ESK	Extraskelatal
ESR	Erythrocyte sedimentation rate
ESSG	European Spondyloarthritis study group
ESSPRI	EULAR Sjögren's syndrome patient reported index
EULAR	European League Against Rheumatism
FBC	Full blood count
GA	Granuloma annulare
GCA	Giant cell arteritis
GPA	Granulomatosis with polyangiitis
GRACE	GRAPPA composite score
GRAPPA	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
H/E	Hematoxylin and eosin
HADD	Hydroxyapatite crystal deposition disease
HAP	Hemiarthroplasty
HAQ-DI	Health assessment questionnaire disability index
HC	Hyaline cartilage
HCQ	Hydroxychloroquine
HIV	Human immunodeficiency virus
HLA	Human leukocyte antigen
HMGCR	3-hydroxy-3-methylglutaryl-CoA reductase
HPV	Human papillomavirus
HRCT	High-resolution computed tomography
HS	Hidradenitis suppurativa
HSP	Henoch-Schönlein purpura
HZ	Herpes zoster
IBM	Inclusion-body myositis
IC	Immune complex
ICOAP	Measure of intermittent and constant osteoarthritis pain
ICU	Intensive care unit
IF	Immunofluorescence
IFN	Interferon
Ig	Immunoglobulin
IgG4-RD	Immunoglobulin G4-related disease
IGRA	Interferon gamma release assay
IL-	Interleukin
ILD	Interstitial lung disease
IP	Interphalangeal
IVIG	Intravenous immunoglobulin
JADAS	Juvenile arthritis disease activity score
JAKi	Janus kinase inhibitors

JIA	Juvenile idiopathic arthritis
KCS	Keratoconjunctivitis sicca
KOOS	Knee injury and osteoarthritis outcome score
LA	Lupus anticoagulant
LD	Lyme disease
LDI	Leeds dactylitis instrument
LE	Lupus erythematosus cell
LEF	Leflunomide
LET	Lupus erythematosus tumidus
LFT	Liver function tests
LIP	Lymphoid interstitial pneumonia
LLDAS	Lupus low disease activity state
MALT	Mucosa-associated lymphoid tissue
MCP	Metacarpophalangeal
MCTD	Mixed connective tissue disease
MDA	Minimal disease activity
mDixon	Modified Dixon
MHC	Major histocompatibility complex
MMF	Mycophenolate mofetil
MPA	Microscopic polyangiitis
MPO	Myeloperoxidase
MRI	Magnetic resonance imaging
mRSS	Modified Rodnan skin score
MSA	Myositis specific autoantibody
mSASSS	Modified Stoke ankylosing spondylitis spinal score
MSK	Musculoskeletal
MST	Modified Schober's test
MSU	Monosodium urate
MSUS	Musculoskeletal ultrasound
MTP	Metatarsophalangeal
mTSS	Modified total Sharp/van der Heijde score
MTX	Methotrexate
NAM	Necrotising autoimmune myositis
NOF	Neck of femur
nr-axSpA	Non-radiographic axial spondyloarthritis
NSAIDs	Non-steroidal anti-inflammatory drugs
NSCLC	Non-small cell lung cancer
NSF	Nephrogenic systemic fibrosis
NSIP	Non-specific interstitial pneumonia
NVC	Nailfold videocapillaroscopy
OA	Osteoarthritis
OARSI	Osteoarthritis Research Society International Committees
OCD	Osteochondritis dissecans
OCI	Osteitis condensans ilii
OMERACT	Outcome measures in rheumatoid arthritis clinical trials

ON	Osteonecrosis
PAD	Peptidylarginine deiminase
PAH	Pulmonary arterial hypertension
PAN	Polyarteritis nodosa
pANCA	Perinuclear antineutrophil cytoplasmic antibodies
PASI	Psoriasis area and severity index
PCL	Posterior cruciate ligament
PD	Proton density
PDS	Power Doppler sonography
PET	Positron emission tomography
PIP	Proximal interphalangeal joint
PM	Polymyositis
PMN	Polymorphonuclear
PR3	Proteinase 3
PROFAD	Profile of fatigue and discomfort
PsA	Psoriatic arthritis
PTPN22	Protein tyrosine phosphatase non-receptor type 22
PUK	Peripheral ulcerative keratitis
QFT	Quantiferon-TB
RA	Rheumatoid arthritis
RANKL	Receptor activator of nuclear factor kappa-B ligand
RAPID3	Routine assessment of patient index data 3 score
RF	Rheumatoid factor
RN	Rheumatoid nodule
RNP	Ribonucleoprotein
ROM	Range of motion
RP	Raynaud's phenomenon
RS3PE	Remitting seronegative symmetrical synovitis with pitting oedema syndrome
RTX	Rituximab
RV	Rheumatoid vasculitis
SAPHO	Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome
SASSS	Stoke ankylosing spondylitis spinal score
SCCJ	Sternocostoclavicular joint
SCL	Scleroderma
SCLE	Subcutaneous lupus erythematosus
SD	Standard deviation
SDAI	Simplified disease activity index
SE	Shared epitope
SELENA-SLEDAI	Safety of estrogen in lupus erythematosus national assessment—systemic lupus erythematosus disease activity measure
SF	Synovial fluid
SI	Sacroiliac

SLE	Systemic lupus erythematosus
SLEDAI	Systemic lupus erythematosus disease activity measure
SLS	Shrinking lung syndrome
Sm	Smith antibodies
SpA	Spondyloarthropathies
SPE	Serum protein electrophoresis
SRI	SLE responder index
SRP	Signal recognition particle
SS	Sjögren's syndrome
SSI	Sicca symptoms inventory
SSZ	Sulphasalazine
ST	Schober's test
TA	Takayasu's arteritis
THA	Total hip arthroplasty
THR	Total hip replacement
TKR	Total knee replacement
TM	Transverse myelitis
TNF-i	Tumour necrosis factor inhibitor
tsDMARDs	Targeted synthetic disease-modifying antirheumatic drugs
TST	Tuberculin skin test
UIP	Usual interstitial pneumonia
ULN	Upper limit of normal
UV	Ultraviolet
VAS	Visual analogue scale
WG	Wegener's granulomatosis
WHO	World Health Organization
WOMAC	Western Ontario and McMaster universities osteoarthritis index